Passeri Luis Augusto, Bértolo Manoel Barros, Abuabara Allan
Faculdade de Ciências Médicas da Universidade Estadual de Campinas – Unicamp, Brazil.
Rev Bras Reumatol. 2011 Jul-Aug;51(4):401-3, 407.
Bisphosphonates are potent inhibitors of bone resorption, and are used in the treatment of osteoporosis and other diseases that cause bone mass loss, such as Paget's disease, bone metastases, and multiple myeloma, to prevent pathological fractures. Since 2003, avascular osteonecrosis of the jaw has been associated with the use of bisphosphonates, mainly intravenous. According to the literature, the occurrence of osteonecrosis of the jaw has ranged from 0.8% to 12% of the patients on bisphosphonates, most of them on prolonged use. Physicians and odontologists should be aware of that potential complication in dental treatment.
双膦酸盐是骨吸收的强效抑制剂，用于治疗骨质疏松症和其他导致骨质流失的疾病，如佩吉特病、骨转移瘤和多发性骨髓瘤，以预防病理性骨折。自2003年以来，颌骨无血管性骨坏死一直与双膦酸盐的使用有关，主要是静脉注射使用。根据文献报道，使用双膦酸盐的患者中，颌骨骨坏死的发生率在0.8%至12%之间，其中大多数是长期使用者。医生和口腔医生在牙科治疗中应意识到这种潜在的并发症。
